- Home
- HTOO vs AIM Comparison
HTOO vs AIM Comparison
Compare HTOO & AIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTOO
- AIM
- Stock Information
- Founded
- HTOO 2020
- AIM 1966
- Country
- HTOO Ireland
- AIM United States
- Employees
- HTOO N/A
- AIM N/A
- Industry
- HTOO Natural Gas Distribution
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HTOO Utilities
- AIM Health Care
- Exchange
- HTOO Nasdaq
- AIM Nasdaq
- Market Cap
- HTOO 9.5M
- AIM 8.8M
- IPO Year
- HTOO N/A
- AIM N/A
- Fundamental
- Price
- HTOO $0.26
- AIM $0.12
- Analyst Decision
- HTOO Strong Buy
- AIM Strong Buy
- Analyst Count
- HTOO 1
- AIM 2
- Target Price
- HTOO $3.50
- AIM $2.75
- AVG Volume (30 Days)
- HTOO 142.7K
- AIM 476.8K
- Earning Date
- HTOO 01-01-0001
- AIM 03-27-2025
- Dividend Yield
- HTOO N/A
- AIM N/A
- EPS Growth
- HTOO N/A
- AIM N/A
- EPS
- HTOO N/A
- AIM N/A
- Revenue
- HTOO $4,440,159.00
- AIM $170,000.00
- Revenue This Year
- HTOO $396.96
- AIM N/A
- Revenue Next Year
- HTOO $284.41
- AIM $1,693.10
- P/E Ratio
- HTOO N/A
- AIM N/A
- Revenue Growth
- HTOO N/A
- AIM N/A
- 52 Week Low
- HTOO $0.25
- AIM $0.11
- 52 Week High
- HTOO $1.57
- AIM $0.62
- Technical
- Relative Strength Index (RSI)
- HTOO 30.98
- AIM 42.13
- Support Level
- HTOO $0.25
- AIM $0.11
- Resistance Level
- HTOO $0.28
- AIM $0.16
- Average True Range (ATR)
- HTOO 0.03
- AIM 0.01
- MACD
- HTOO 0.00
- AIM 0.00
- Stochastic Oscillator
- HTOO 8.21
- AIM 5.00
About HTOO Fusion Fuel Green PLC
Fusion Fuel Green PLC is a company that has developed a Green Hydrogen production technology. It is focused on generating cost-effective and competitively priced Green Hydrogen.
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.